Abstract
Hepatocellular carcinoma (HCC), cholangiocarcinoma, and pancreatic ductal adenocarcinoma (PDAC) are the most common primary hepatobiliary and pancreatic cancers and are associated with poor survival. With improvements in anticancer therapy during recent decades, assessment of treatment response has become more significant and different methods have been utilized in evaluating response to therapy. While conventional methods rely solely on size reduction, newer techniques focus on changes in tumor functional features as a response to treatment. In assessing HCC tumors response, WHO and RECIST only considered tumor shrinkage as a response to treatment. With the introduction of locoregional and molecular-targeted therapies in HCC treatment, the limitations of size-based criteria were addressed by development of new criteria that considered functional imaging parameters such as tumor enhancement. Functional criteria such as Choi, RECICL, EASL criteria, and mRECIST mostly focus on the viability/functionality of the tumor and are considered more accurate in assessing treatment response. In addition, new advanced technologies like CTPI, DWI, IVIM, MRS, MR-PWI, FDG-PET/CT, and PET/MRI can detect response at molecular level and can assess treatment response before any morphological changes take place. Similar to HCC, functional criteria using modalities like FDG-PET/CT, PET/MRI, DCE-MRI, and DWI are also being utilized in the evaluation of cholangiocarcinoma and PDAC in addition to conventional size criteria to detect early changes of treatment response.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG (2010) Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 256(2):441–449. https://doi.org/10.1148/radiol.10091733
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M (2013) Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109:926. https://doi.org/10.1038/bjc.2013.415. https://www.nature.com/articles/bjc2013415#supplementary-information
Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M (2014) Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 49(12):1578–1587. https://doi.org/10.1007/s00535-014-0936-0
Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, Kulik L, Miller F, Yaghmai V, Murthy R, Larson A, Omary RA, Salem R (2008) Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28(1):81–99. https://doi.org/10.1148/rg.281065721
Bali MA, Metens T, Denolin V, Delhaye M, Demetter P, Closset J, Matos C (2011) Tumoral and nontumoral pancreas: correlation between quantitative dynamic contrast-enhanced MR imaging and histopathologic parameters. Radiology 261(2):456–466. https://doi.org/10.1148/radiol.11103515
Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR (2011a) Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 260(3):752–761. https://doi.org/10.1148/radiol.11102330
Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR (2011b) Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr 35(2):167–173. https://doi.org/10.1097/RCT.0b013e3182004bfb
Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR (2013) Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology 268(2):431–439. https://doi.org/10.1148/radiol.13121637
Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR (2014) Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol 83(3):487–496. https://doi.org/10.1016/j.ejrad.2013.11.016
Boninsegna E, Negrelli R, Zamboni GA, Avesani G, Manfredi R, Pozzi-Mucelli R (2017) Assessing treatment response in pancreatic cancer: role of different imaging criteria. In: ECR 2017
Braren R, Altomonte J, Settles M, Neff F, Esposito I, Ebert O, Schwaiger M, Rummeny E, Steingoetter A (2011) Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol 55(5):1034–1040. https://doi.org/10.1016/j.jhep.2011.01.049
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430
Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS (2014) Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol 25(2):256–265. https://doi.org/10.1016/j.jvir.2013.10.056
Cassinotto C, Mouries A, Lafourcade JP, Terrebonne E, Belleannee G, Blanc JF, Lapuyade B, Vendrely V, Laurent C, Chiche L, Wagner T, Sa-Cunha A, Gaye D, Trillaud H, Laurent F, Montaudon M (2014) Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology 273(1):108–116. https://doi.org/10.1148/radiol.14132914
Chalian H, Tochetto SM, Tore HG, Rezai P, Yaghmai V (2012) Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. Radiology 262(3):853–861. https://doi.org/10.1148/radiol.11110106
Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF (2014) Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 273(3):746–758. https://doi.org/10.1148/radiol.14140033
Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC (2006) Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants—initial experience. Radiology 239(2):448–456. https://doi.org/10.1148/radiol.2392042202
Chen G, Ma DQ, He W, Zhang BF, Zhao LQ (2008) Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 14(37):5738–5743
Chen BB, Tien YW, Chang MC, Cheng MF, Chang YT, Wu CH, Chen XJ, Kuo TC, Yang SH, Shih IL, Lai HS, Shih TT (2016) PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis. Eur J Nucl Med Mol Imaging 43(10):1753–1764. https://doi.org/10.1007/s00259-016-3356-y
Chen X, Oshima K, Schott D, Wu H, Hall W, Song Y, Tao Y, Li D, Zheng C, Knechtges P, Erickson B, Li XA (2017) Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: an exploratory study. PLoS One 12(6):e0178961. https://doi.org/10.1371/journal.pone.0178961
Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183(6):1619–1628. https://doi.org/10.2214/ajr.183.6.01831619
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759. https://doi.org/10.1200/jco.2006.07.3049
Choi MH, Lee YJ, Yoon SB, Choi JI, Jung SE, Rha SE (2018) MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome. Abdominal Radiol (New York). https://doi.org/10.1007/s00261-018-1681-2
Ciaravino V, Cardobi N, DER R, Capelli P, Melisi D, Simionato F, Marchegiani G, Salvia R, D’Onofrio M (2018) CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy. Anticancer Res 38(8):4889–4895. https://doi.org/10.21873/anticanres.12803
Corona-Villalobos CP, Kamel IR (2014) Functional volumetric MRI in assessing treatment response to intra-arterial therapy of primary and secondary liver tumors. J Comput Assist Tomogr 38(4):513–517. https://doi.org/10.1097/rct.0000000000000072
Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD (2014) A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Translational Oncol 7(5):644–649. https://doi.org/10.1016/j.tranon.2014.07.005
Di Bisceglie AM (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26(3 Suppl 1):34s–38s. https://doi.org/10.1002/hep.510260706
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Epelbaum R, Frenkel A, Haddad R, Sikorski N, Strauss LG, Israel O, Dimitrakopoulou-Strauss A (2013) Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT. J Nucl Med 54(1):12–18. https://doi.org/10.2967/jnumed.112.107466
Fattahi R, Balci NC, Perman WH, Hsueh EC, Alkaade S, Havlioglu N, Burton FR (2009) Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 29(2):350–356. https://doi.org/10.1002/jmri.21651
Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55(6):1309–1316. https://doi.org/10.1016/j.jhep.2011.03.007
Gonzalez-Guindalini FD, Botelho MP, Harmath CB, Sandrasegaran K, Miller FH, Salem R, Yaghmai V (2013) Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 33(6):1781–1800. https://doi.org/10.1148/rg.336135511
Guo Z, Zhang Q, Li X, Jing Z (2015) Intravoxel incoherent motion diffusion weighted MR imaging for monitoring the instantly therapeutic efficacy of radiofrequency ablation in rabbit VX2 tumors without evident links between conventional perfusion weighted images. PLoS One 10(5):e0127964. https://doi.org/10.1371/journal.pone.0127964
Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF, Kamel IR (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264(1):285–294. https://doi.org/10.1148/radiol.12112142
Hayano K, Lee SH, Sahani DV (2015) Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 25(2):121–128. https://doi.org/10.4103/0971-3026.155835
Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20(1):30–38. https://doi.org/10.1016/j.jvir.2008.09.034
Hurley JD, Ellison EH (1960) Chemotherapy of solid cancer arising from the gastro-intestinal tract. Ann Surg 152:568–582
Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T (1998) Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. Am J Roentgenol 170(2):397–402. https://doi.org/10.2214/ajr.170.2.9456953
Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE (1985) Role of liver transplantation in cancer therapy. Ann Surg 202(4):401–407
Joo I, Lee JM, Han JK, Choi BI (2014) Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 272(2):417–426. https://doi.org/10.1148/radiol.14131165
Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind J-FH (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17(3):505–512. https://doi.org/10.1097/01.RVI.0000200052.02183.92
Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF (2007) Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18(1 Pt 1):49–56. https://doi.org/10.1016/j.jvir.2006.10.005
Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind J-FH (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250(2):466–473. https://doi.org/10.1148/radiol.2502072222
Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756. https://doi.org/10.1002/cncr.27636
Kele PG, van der Jagt EJ (2010) Diffusion weighted imaging in the liver. World J Gastroenterol 16(13):1567–1576
Kim JW, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH (2012a) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 82(3):1172–1178. https://doi.org/10.1016/j.ijrobp.2010.11.076
Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, Kwon JH (2012b) Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging 46(2):102–110. https://doi.org/10.1007/s13139-012-0138-8
Kim JH, Lee JM, Park JH, Kim SC, Joo I, Han JK, Choi BI (2013) Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment—a preliminary study. Radiology 266(1):185–196. https://doi.org/10.1148/radiol.12120111
Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M (2010) Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 40(7):686–692. https://doi.org/10.1111/j.1872-034X.2010.00674.x
Kuo YT, Li CW, Chen CY, Jao J, Wu DK, Liu GC (2004) In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging 19(5):598–604. https://doi.org/10.1002/jmri.20046
Lee SS, Byun JH, Park BJ, Park SH, Kim N, Park B, Kim JK, Lee M-G (2008) Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J Magn Reson Imaging 28(4):928–936. https://doi.org/10.1002/jmri.21508
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60. https://doi.org/10.1055/s-0030-1247132
Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Rios J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM (2017) Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 66(6):1166–1172. https://doi.org/10.1016/j.jhep.2017.01.012
Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet (London, England) 363(9414):1049–1057. https://doi.org/10.1016/s0140-6736(04)15841-8
Li H, Zeng MS, Zhou KR, Jin DY, Lou WH (2006) Pancreatic adenocarcinoma: signs of vascular invasion determined by multi-detector row CT. Br J Radiol 79(947):880–887. https://doi.org/10.1259/bjr/19684199
Lin M, Tian M-M, Zhang W-P, Xu L, Jin P (2016) Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma. OncoTargets Ther 9:7029–7037. https://doi.org/10.2147/OTT.S112555
Liver Cancer Survival Rates (n.d.). https://www.cancer.org/cancer/liver-cancer/detection-diagnosis-staging/survival-rates.html
MartÃn Noguerol T, Sánchez-González J, MartÃnez Barbero JP, GarcÃa-Figueiras R, Baleato-González S, Luna A (2016) Clinical imaging of tumor metabolism with 1H magnetic resonance spectroscopy. Magnetic Resonance Imaging Clinics 24(1):57–86. https://doi.org/10.1016/j.mric.2015.09.002
Miles KA, Hayball M, Dixon AK (1991) Colour perfusion imaging: a new application of computed tomography. Lancet (London, England) 337(8742):643–645
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214
Minocha J, Lewandowski RJ (2015) Assessing imaging response to therapy. Radiol Clin North Am 53(5):1077–1088. https://doi.org/10.1016/j.rcl.2015.05.010
Nagamachi S, Nishii R, Wakamatsu H, Mizutani Y, Kiyohara S, Fujita S, Futami S, Sakae T, Furukoji E, Tamura S, Arita H, Chijiiwa K, Kawai K (2013) The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT. Ann Nucl Med 27(6):554–563. https://doi.org/10.1007/s12149-013-0719-3
Niwa T, Ueno M, Ohkawa S, Yoshida T, Doiuchi T, Ito K, Inoue T (2009) Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol 82(973):28–34. https://doi.org/10.1259/bjr/43911400
Ortega Lopez N (2015) PET/computed tomography in evaluation of transarterial chemoembolization. PET clinics 10(4):507–517. https://doi.org/10.1016/j.cpet.2015.05.006
Pancreatic Cancer Survival Rates, by Stage (n.d.). https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html
Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, Zarghampour M, Fouladi DF, Liddell R, Kamel IR (2018) Unresectable intrahepatic cholangiocarcinoma: multiparametric MR imaging to predict patient survival. Radiology 288(1):109–117. https://doi.org/10.1148/radiol.2018171593
Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G (2011) Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 104(2):155–161. https://doi.org/10.1002/jso.21954
Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, Ryu RK, Miller FH, Larson AC, Salem R, Omary RA (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19(8):1180–1186. https://doi.org/10.1016/j.jvir.2008.05.002
Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB 3rd, Nemcek AA Jr, Omary R, Salem R (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303(11):1062–1069. https://doi.org/10.1001/jama.2010.262
Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S (2014) Alternative response criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 19(4):394–402. https://doi.org/10.1634/theoncologist.2013-0114
Saha SK, Zhu AX, Fuchs CS, Brooks GA (2016) Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21(5):594–599. https://doi.org/10.1634/theoncologist.2015-0446
Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA (2012) State-of-the-art PET/CT of the pancreas: current role and emerging indications. Radiographics 32(4):1133–1158.; ; discussion 1158–1160. https://doi.org/10.1148/rg.324115143
Schwartz LH, Seymour L, Litiere S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E (2016) RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer (Oxford England: 1990) 62:138–145. https://doi.org/10.1016/j.ejca.2016.03.082
Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schutte K, Stubs P, Kettner E, Pech M, Amthauer H, Ricke J (2016) Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract 2016:8732521. https://doi.org/10.1155/2016/8732521
Shirota N, Saito K, Sugimoto K, Takara K, Moriyasu F, Tokuuye K (2016) Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. Cancer Imaging 16(1). https://doi.org/10.1186/s40644-016-0059-3
Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ (2015) Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol 70(2):128–137. https://doi.org/10.1016/j.crad.2014.09.020
Sun X-J, Quan X-Y, Huang F-H, Xu Y-K (2005) Quantitative evaluation of diffusion-weighted magnetic resonance imaging of focal hepatic lesions. World J Gastroenterol 11(41):6535–6537. https://doi.org/10.3748/wjg.v11.i41.6535
Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH (2018) (18)F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging 45(3):384–391. https://doi.org/10.1007/s00259-017-3871-5
Survival Rates for Bile Duct Cancer (2018). https://www.cancer.org/cancer/bile-duct-cancer/detection-diagnosis-staging/survival-by-stage.html. Published 2018
Syha R, Grozinger G, Grosse U, Maurer M, Zender L, Horger M, Nikolaou K, Ketelsen D (2016) Parenchymal blood volume assessed by C-arm-based computed tomography in immediate posttreatment evaluation of drug-eluting bead transarterial chemoembolization in hepatocellular carcinoma. Invest Radiol 51(2):121–126. https://doi.org/10.1097/rli.0000000000000215
Sylvester R (1980) WHO handbook for reporting results of cancer treatment: WHO offset publication #48 World Health Organization, Geneva, 1979, 45 pages, 6 Swiss Francs. Control Clin Trials 1(3):276–277. https://doi.org/10.1016/0197-2456(80)90009-4
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F (2018) Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol 28(9):3611–3620. https://doi.org/10.1007/s00330-018-5393-3
Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Worner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, Esposito I, Braren R, Siveke JT (2017) Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Sci Rep 7(1):17038. https://doi.org/10.1038/s41598-017-16826-z
Vecchiarelli S, Macchini M, Grassi E, Ferroni F, Ciccarese F, Calculli L, Ricci C, Casadei R, Pezzilli R, Biasco G, Marco MD (2013) Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer. J Clin Oncol 31(15 Suppl):e15069. https://doi.org/10.1200/jco.2013.31.15_suppl.e15069
ter Voert EGW, Heijmen L, van Laarhoven HWM, Heerschap A (2011) In vivo magnetic resonance spectroscopy of liver tumors and metastases. World J Gastroenterol 17(47):5133–5149. https://doi.org/10.3748/wjg.v17.i47.5133
Vossen JA, Buijs M, Kamel IR (2006) Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 9(3):125–132. https://doi.org/10.1053/j.tvir.2007.02.004
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122s–150s. https://doi.org/10.2967/jnumed.108.057307
Watanabe H, Kanematsu M, Goshima S, Kajita K, Kawada H, Noda Y, Tatahashi Y, Kawai N, Kondo H, Moriyama N (2014) Characterizing focal hepatic lesions by free-breathing intravoxel incoherent motion MRI at 3.0 T. Acta Radiol (Stockholm Sweden: 1987) 55(10):1166–1173. https://doi.org/10.1177/0284185113514966
Weber SM, Ribero D, O’Reilly EM, Kokudo N, Miyazaki M, Pawlik TM (2015) Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17(8):669–680. https://doi.org/10.1111/hpb.12441
Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, Gerken G, Yang D, Schlaak JF (2013) Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncol Lett 6(6):1707–1712. https://doi.org/10.3892/ol.2013.1612
Woo S, Lee JM, Yoon JH, Joo I, Han JK, Choi BI (2014) Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. Radiology 270(3):758–767. https://doi.org/10.1148/radiol.13130444
Wray CJ, Ahmad SA, Matthews JB, Lowy AM (2005) Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128(6):1626–1641
Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B (2013) Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 201(1):80–96. https://doi.org/10.2214/ajr.13.10706
Yang K, Zhang XM, Yang L, Xu H, Peng J (2016a) Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 22(20):4835–4847. https://doi.org/10.3748/wjg.v22.i20.4835
Yang Z, Sun S, Chen Y, Li R (2016b) Application of single voxel 1H magnetic resonance spectroscopy in hepatic benign and malignant lesions. Med Sci Monit 22:5003–5010
Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R (2017) Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol 8(1):127–138. https://doi.org/10.21037/jgo.2016.12.04
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ameli, S., Shaghaghi, M., Kamel, I.R., Zaheer, A. (2020). Therapy Response Imaging in Hepatobiliary and Pancreatic Malignancies. In: Nishino, M. (eds) Therapy Response Imaging in Oncology. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/978-3-030-31171-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-31171-1_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31170-4
Online ISBN: 978-3-030-31171-1
eBook Packages: MedicineMedicine (R0)